IC 270 is a SYK kinase inhibitor combined with a commercially available antihistamine to treat acute and chronic allergic conjunctivitis, inflammatory condition of the eye due to exposure to pollen or mold. It has the potential to be a leading allergy medicine that can alleviate itch, redness, and the inflammatory effect associated with an allergic response.

The ability to treat itch as well as redness/inflammation could make IC 270 the first-in-class ocular allergy combination product

Since the SYK kinase activation is the first step in the cascade leading to histamine release, there is the potential that SYK kinase inhibition may have an additive or synergistic effect with the antihistamine in reducing itch when IC 270 is administered in a chronic allergy setting

IC 270 uses our SYK kinase inhibitor that is able to block multiple downstream signaling pathways leading to different ophthalmic ailments, including dry eye.

IC 702 is a next generation broad-spectrum ocular antibiotic with a unique MOA designed to be highly effective against resistant bacteria. It has a greater potency compared to currently marketed ocular antibiotics. It maintains potency against fluoroquinolone-resistant and multi-drug resistant clinical isolates, including methicillin-resistant staphylococcus aureus (MRSA), by uniquely targeting topoisomerase IV, DNA gyrase, and DNA primase.

IC 805 is a potent analgesic and anti-inflammatory compound. It harnesses the power of DENKI technology to control neuropathic pain and pain associated with dry eye in chronic cases. Its sister compound, IC 800, has acute applications, like post-surgical pain management from cataract surgery.

IC 805 uses our proprietary molecule DENKI to inhibit enzymes that degrade the body’s natural response to pain. DENKI can increase the local concentrations of enkephalins, the opioid peptides produced by the body to relieve pain.